ATYR PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

ATYR ▼ -2.78% at T+5d

NEUTRAL call ✗ call lost -2.78% · α vs SPY -3.74% · entry $0.5040 → $0.4900

Next anchor: T+20d in 5d

Currently $0.4556 · -9.60% from $0.5040 entry

Entry anchored
May 15, 07:45 AM ET
via Databento tick

T+1d

+3.17%

call +3.17% · α +3.24%

$0.5200

settled 23d ago

T+5d

-2.78%

call -2.78% · α -3.74%

$0.4900

settled 19d ago

T+20d

—

call — · α —

—

in 5d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

aTyr Pharma reported Q1 2026 EPS of -$0.14, a 3.9% beat vs consensus of -$0.15, on no revenue. The company announced plans to file an IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis following a Type C FDA meeting, and is on track to complete enrollment in the Phase 2 EFZO-CONNECT SSc-ILD study in H1 2026. Cash position of $68.3M provides runway into 2027, but the stock remains a binary-risk clinical-stage biotech with no approved products.

Actionable Insight

The EPS beat is modest and the company remains pre-revenue. The key catalyst is the June 2026 IND filing for Phase 3 pulmonary sarcoidosis study — monitor for updates on FDA feedback and trial design. Cash runway of $68.3M supports operations into 2027 but likely requires future financing. The stock is driven by pipeline milestones, not quarterly financials.

Key Facts

Q1 2026 EPS -$0.14 vs consensus -$0.15 (3.9% beat)
Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026
Plans to file IND in June 2026 for Phase 3 study of efzofitimod in pulmonary sarcoidosis
Phase 2 EFZO-CONNECT study in SSc-ILD on track to complete enrollment in H1 2026
Net loss attributable to aTyr Pharma: $10.8M in Q1 2026 vs $14.9M in Q1 2025
R&D expenses: $7.3M in Q1 2026, down from $11.8M in Q1 2025

Financial Impact

EPS beat of 3.9% on a -$0.15 consensus; cash burn of ~$12.6M in Q1 2026

epscashoperating expenses

Risk Factors

Clinical-stage biotech with no approved products or revenue
Phase 3 pulmonary sarcoidosis study carries binary risk of failure
Cash burn rate of ~$12.6M/quarter implies ~5 quarters of runway; likely need to raise capital
Phase 2 EFZO-CONNECT SSc-ILD study enrollment completion is pending

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

50% bullish (16 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3295781

8 reports for ATYR

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ATYR — sortable, filterable
	Type				Now
Jun 8, 2026 1d ago	8-K BEARISH ★ 7/10	$0.4430 awaiting T+1	awaiting T+1	—	$0.4556 (−2.84%)
Jun 1, 2026 8d ago	8-K NEUTRAL ★ 4/10	$0.5200 $0.5001	▼ −3.83%	▼ −3.13%	$0.4556 (−12.38%)
May 15, 2026 25d ago	8-K BULLISH ★ 5/10	$0.5040 $0.5200	▲ +3.17%	▲ +3.24%	$0.4556 (−9.60%)
May 15, 2026 25d ago	Press Release NEUTRAL ★ 5/10	$0.5040 $0.5200	▲ +3.17%	▲ +3.24%	$0.4556 (−9.60%)
May 11, 2026 29d ago	8-K MIXED ★ 6/10	$0.5300 $0.5300	· 0.00%	▼ −0.54%	$0.4556 (−14.04%)
Mar 26, 2026 10w ago	DEFA14A NEUTRAL ★ 2/10	$0.7520 $0.7310	▼ −2.79%	▼ −2.43%	$0.4556 (−39.41%)
Mar 5, 2026 13w ago	8-K MIXED ★ 6/10	$0.8240 $0.9000	▲ +9.22%	▲ +8.38%	$0.4556 (−44.71%)
Mar 5, 2026 13w ago	Press Release MIXED ★ 6/10	$0.8240 $0.9000	▲ +9.22%	▲ +8.38%	$0.4556 (−44.71%)

US Market Status

Market Closed — Opens Thu (9h 47m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access